Yahoo Web Suche

Suchergebnisse

1. www.boerse.de › aktien › Alnylam-Pharmaceuticals-AktieAlnylam Pharmaceuticals AKTIE | Aktienkurs & News - boerse.de

   www.boerse.de › aktien › Alnylam-Pharmaceuticals-Aktie

   • Im Cache

   Vor einem Tag · Alnylam Pharmaceuticals, gegründet im Jahr 2002, hat sich auf die Entwicklung von RNA-Interferenz (RNAi)-Therapien zur Behandlung von genetisch bedingten Erkrankungen spezialisiert.

   • Branche: Chemie, Pharma, Bio- und Medizintechnik
   • Land: USA

   • ISIN: US02043Q1076
   • WKN: A0CBCK

2. www.bloomberg.com › quote › ALNY:USALNY: Alnylam Pharmaceuticals Inc Stock Price Quote - Bloomberg

   www.bloomberg.com › quote › ALNY:US

   • Im Cache

   Vor 4 Tagen · Stock analysis for Alnylam Pharmaceuticals Inc (ALNY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

   • Mitarbeiter: 2.1K

3. stockanalysis.com › stocks › alnyAlnylam Pharmaceuticals, Inc. (ALNY) - Stock Analysis

   stockanalysis.com › stocks › alny

   • Im Cache

   Vor 4 Tagen · Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

   • Market Cap: 28.20B
   • Revenue (ttm): 2.00B

   • Net Income (ttm): 332.08M
   • Shares Out: 126.49M

4. seekingalpha.com › symbol › ALNYALNY Alnylam Pharmaceuticals, Inc. - Seeking Alpha

   seekingalpha.com › symbol › ALNY

   • Im Cache

   Vor 4 Tagen · Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

5. Aktuelle Nachrichten

   • 

     YAHOO!Finance

     Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win

     vor 1 Tag

   • 

     YAHOO!Finance

     Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings

     vor 4 Tagen

   • bovnews

     Alnylam Pharmaceuticals Inc (ALNY) Stock to return to profitability in the near future

     Goldman raised the price target for the Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) stock from “a Buy” to “a Neutral”. The rating was released on February 16, 2024, according to finviz. The research report from Wells Fargo has initiated the stock to Equal Weight, with a price target set at $171.

     vor 6 Tagen

   • Benzinga.com

     $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

     vor 6 Tagen

   • Medscape

     Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis

     vor 19 Stunden

6. www.marketbeat.com › stocks › NASDAQAlnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis -...

   www.marketbeat.com › stocks › NASDAQ

   • Im Cache

   Vor 4 Tagen · Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

   • 4.7/5
   • Email: investors@alnylam.com

   • Telefon: (617) 551-8200
   • Mitarbeiter: 2.1K

7. simplywall.st › nasdaq-alny › alnylam-pharmaceuticalsAlnylam Pharmaceuticals NasdaqGS:ALNY Stock Report - Simply Wall...

   simplywall.st › nasdaq-alny › alnylam-pharmaceuticals

   • Im Cache

   Vor 5 Tagen · 1Y. 29.1% Updated. 03 Jul, 2024. Data. Company Financials +. 29 Analysts. ALNY Stock Overview. A biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. About the company. Rewards. Trading at 50% below our estimate of its fair value.

8. www.finanzen100.de › aktien › alnylam-pharmaceuticals-wkn-a0Alnylam Pharmaceuticals Aktie - Kurs - Finanzen100

   www.finanzen100.de › aktien › alnylam-pharmaceuticals-wkn-a0

   Vor 5 Tagen · Alnylam Pharmaceuticals Aktie: Aktueller Aktienkurs Charts Nachrichten Realtime WKN: A0CBCK | ISIN: US02043Q1076.